GRFS Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals Plc has a net margin of 7.69% compared to Grifols SA's net margin of --. Grifols SA's return on equity of 5.73% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 18.46%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7468.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Grifols SA, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.668, which suggesting that the stock is 33.199% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.85%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Grifols SA's price-to-earnings ratio is 15.26x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.77x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion AS has a net margin of 7.69% compared to Grifols SA's net margin of -64.14%. Grifols SA's return on equity of 5.73% beat Evaxion AS's return on equity of --.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 18.46%. On the other hand Evaxion AS has an analysts' consensus of $14.19 which suggests that it could grow by 179.28%. Given that Evaxion AS has higher upside potential than Grifols SA, analysts believe Evaxion AS is more attractive than Grifols SA.

Grifols SA has a beta of 0.668, which suggesting that the stock is 33.199% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.85%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Evaxion AS quarterly revenues of $37.5K. Grifols SA's net income of $167.6M is higher than Evaxion AS's net income of -$4.9M. Notably, Grifols SA's price-to-earnings ratio is 15.26x while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.77x versus 3.41x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group Plc has a net margin of 7.69% compared to Grifols SA's net margin of -2923.31%. Grifols SA's return on equity of 5.73% beat Mereo BioPharma Group Plc's return on equity of -70.81%.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 18.46%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.72 which suggests that it could grow by 652.81%. Given that Mereo BioPharma Group Plc has higher upside potential than Grifols SA, analysts believe Mereo BioPharma Group Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.668, which suggesting that the stock is 33.199% less volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.85%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Grifols SA's net income of $167.6M is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, Grifols SA's price-to-earnings ratio is 15.26x while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.77x versus 154.38x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech Plc has a net margin of 7.69% compared to Grifols SA's net margin of -31.41%. Grifols SA's return on equity of 5.73% beat Trinity Biotech Plc's return on equity of --.

Grifols SA has a consensus price target of $11.10, signalling upside risk potential of 18.46%. On the other hand Trinity Biotech Plc has an analysts' consensus of -- which suggests that it could grow by 1944.15%. Given that Trinity Biotech Plc has higher upside potential than Grifols SA, analysts believe Trinity Biotech Plc is more attractive than Grifols SA.

Grifols SA has a beta of 0.668, which suggesting that the stock is 33.199% less volatile than S&P 500. In comparison Trinity Biotech Plc has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.46%.

Grifols SA has a quarterly dividend of $0.17 per share corresponding to a yield of 1.85%. Trinity Biotech Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Grifols SA pays -- of its earnings as a dividend. Trinity Biotech Plc pays out -- of its earnings as a dividend.

Grifols SA quarterly revenues are $2.2B, which are larger than Trinity Biotech Plc quarterly revenues of $15.2M. Grifols SA's net income of $167.6M is higher than Trinity Biotech Plc's net income of -$4.8M. Notably, Grifols SA's price-to-earnings ratio is 15.26x while Trinity Biotech Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Grifols SA is 0.77x versus 0.26x for Trinity Biotech Plc. Usually stocks with elevated PS ratios are considered overvalued.